AstraZeneca file sNDA for Symbicort for Asthma in children « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

AstraZeneca file sNDA for Symbicort for Asthma in children

Posted on June 4, 2008 by crimsoncanary

AstraZeneca have filed supplemental New Drug Application to the FDA for approval of Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in paediatric patients ages 6 to 11 years old.

Filed under: gpcr | Tagged: agonist, Astrazeneca, Beta 2 adrenoceptor, Formoterol, Symbocort

« Gdansk University publish series of dual alpha2 adrenoceptor/imidazoline I1 agonists Allergan to filed NDA for bimatoprost as a treatment to stimulate eyelash growth »

Leave a Reply